XML 138 R3.htm IDEA: XBRL DOCUMENT v3.20.1
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended
Mar. 31, 2020
Mar. 31, 2019
Income Statement [Abstract]    
Revenues $ 13,076 $ 8,071
Operating expenses:    
Research and development 41,479 34,850
General and administrative 16,119 17,118
Total operating expenses 57,598 51,968
Loss from operations (44,522) (43,897)
Interest and other income, net 1,548 1,694
Net loss (42,974) (42,203)
Net loss attributable to non-controlling interest (61) (53)
Net loss to Sangamo Therapeutics, Inc. stockholders $ (42,913) $ (42,150)
Basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in dollars per share) $ (0.37) $ (0.41)
Shares used in computing basic and diluted net loss per share attributable to Sangamo Therapeutics, Inc. stockholders (in shares) 116,060 102,270